Corrigendum: The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study (Front. Cardiovasc. Med., (2022), 9, (791446), 10.3389/fcvm.2022.791446)

Soo Jin Na, Jong Chan Youn, Hye Sun Lee, Soyoung Jeon, Hae Young Lee, Hyun Jai Cho, Jin Oh Choi, Eun Seok Jeon, Sang Eun Lee, Min Seok Kim, Jae Joong Kim, Kyung Kuk Hwang, Myeong Chan Cho, Shung Chull Chae, Seok Min Kang, Dong Ju Choi, Byung Su Yoo, Kye Hun Kim, Byung Hee Oh, Sang Hong Baek

Research output: Contribution to journalComment/debate

3 Scopus citations

Abstract

In the original article, there was an error. An author name was incorrectly spelled as “Kye Hoon Kim.” The correct spelling is “Kye Hun Kim.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number888829
JournalFrontiers in Cardiovascular Medicine
Volume9
DOIs
StatePublished - 4 Apr 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022, Na, Youn, Lee, Jeon, Lee, Cho, Choi, Jeon, Lee, Kim, Kim, Hwang, Cho, Chae, Kang, Choi, Yoo, Kim, Oh and Baek.

Keywords

  • acute heart failure syndrome
  • drug therapy
  • mineralocorticoid receptor antagonists
  • outcome
  • spironolactone

Fingerprint

Dive into the research topics of 'Corrigendum: The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study (Front. Cardiovasc. Med., (2022), 9, (791446), 10.3389/fcvm.2022.791446)'. Together they form a unique fingerprint.

Cite this